Tex.
Health & Safety Code Section 481.0762
Monitoring by Regulatory Agency
(a)
Each regulatory agency that issues a license, certification, or registration to a prescriber shall promulgate specific guidelines for prescribers regulated by that agency for the responsible prescribing of opioids, benzodiazepines, barbiturates, or carisoprodol.(b)
A regulatory agency that issues a license, certification, or registration to a prescriber shall periodically access the information submitted to the board under Sections 481.074 (Prescriptions)(q) and 481.075 (Schedule Ii Prescriptions) to determine whether a prescriber is engaging in potentially harmful prescribing patterns or practices.(c)
If the board sends a prescriber an electronic notification authorized under Section 481.0761 (Rules; Authority to Contract)(i), the board shall immediately send an electronic notification to the appropriate regulatory agency.(d)
In determining whether a potentially harmful prescribing pattern or practice is occurring, the appropriate regulatory agency, at a minimum, shall consider:(1)
the number of times a prescriber prescribes opioids, benzodiazepines, barbiturates, or carisoprodol; and(2)
for prescriptions described by Subdivision (1), patterns of prescribing combinations of those drugs and other dangerous combinations of drugs identified by the board.(e)
If, during a periodic check under this section, the regulatory agency finds evidence that a prescriber may be engaging in potentially harmful prescribing patterns or practices, the regulatory agency may notify that prescriber.(f)
A regulatory agency may open a complaint against a prescriber if the agency finds evidence during a periodic check under this section that the prescriber is engaging in conduct that violates this subchapter or any other statute or rule.
Source:
Section 481.0762 — Monitoring by Regulatory Agency, https://statutes.capitol.texas.gov/Docs/HS/htm/HS.481.htm#481.0762 (accessed Jun. 5, 2024).
